🔎 Trials Near Me

Home › Follicular Lymphoma › Illinois

Pag-aaral pangklinika para sa Follicular Lymphoma sa Illinois

14 pag-aaral para sa Follicular Lymphoma ang naghahanap ng mga kalahok sa mga site sa Illinois.

Mga Lungsod sa Illinois

Opisyal na teksto ng pag-aaral (English)

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • The University of Chicago Medical Center (UCMC), Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  • OSF Saint Joseph Medical Center, Bloomington
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • at 24 pa
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07215910

A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

  • Northwestern Memorial Hospital, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT05765812

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT06860594

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  • Research Site, Evanston
  • Research Site, Peoria
Nagre-recruitPhase 3
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT06549595

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Chicago, Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT05303519

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT06526793

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

  • Ruth M. Rothstein CORE Center, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06651177

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Northwestern University, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  • Local Institution - 0240, Arlington Heights
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 20, 2026 · NCT06911502

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • University of Illinois at Chicago Cancer Center, Chicago
Nagre-recruitPhase 1/2
Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • The University of Chicago Medical Center, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Northwestern Memorial Hospital, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.